4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,220,199 | -16.2% | 331,516 | +19.0% | 0.00% | 0.0% |
| Q2 2023 | $5,036,127 | +67084.2% | 278,701 | -17.4% | 0.00% | -60.0% |
| Q4 2022 | $7,496 | -99.6% | 337,483 | +29.7% | 0.01% | +400.0% |
| Q3 2022 | $2,091,000 | +9.1% | 260,109 | -5.2% | 0.00% | 0.0% |
| Q2 2022 | $1,916,000 | +64.7% | 274,428 | +256.8% | 0.00% | 0.0% |
| Q1 2022 | $1,163,000 | -72.2% | 76,924 | -50.5% | 0.00% | -66.7% |
| Q3 2021 | $4,187,000 | -50.6% | 155,258 | -55.9% | 0.00% | -40.0% |
| Q2 2021 | $8,477,000 | -41.5% | 352,051 | +5.4% | 0.01% | -50.0% |
| Q1 2021 | $14,495,000 | +1.6% | 334,149 | -2.9% | 0.01% | 0.0% |
| Q4 2020 | $14,271,000 | – | 344,283 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |